EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq:GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company’s Board of Directors has granted nine employees nonqualified stock options to purchase an aggregate of 42,550 shares of its common stock with an exercise price of $3.17, which is equal to the closing price of Gritstone’s common stock on April 21, 2022, the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20logo%20on%20phone-by%20WonderPix%20via%20Shutterstock.jpg)
